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Abstract 
Ankylosing spondylitis (AS) is a systemic autoimmune disorder that induces ankylosis of 
the spine (fusion of the vertebrae at their various joints) and inflammatory arthritis of 
peripheral joints among other symptoms. Overexpression of cytokines, the presence of 
genetic mutations not exclusive to the human leucocyte antigen (HLA)-B27 region, and 
environmental factors all have large roles in the progressive development of AS. 
Although a definitive pathology continues to be sought after, researchers believe the 
adaptive immune system in AS patients attacks fibrocartilaginous entheses (supportive 
connective tissue between bone and attached structures like tendon, ligament, and fascia). 
AS markedly reduces proper systemic functioning in several areas of human physiology, 
including the musculoskeletal, cardiovascular, neurological, psychiatric, and reproductive 
systems in both genders. A diagnosis for this disease requires the presentation of several 
qualifying symptoms, namely chronic inflammatory back pain, peripheral joint arthritis, 
enthesitis (inflammation of the enthesis not associated with a joint), uveitis (inflammation 
of the uvea or inner eye layer), and positive response to non-steroidal anti-inflammatory 
drugs (NSAIDs), with radiological support through x-ray or magnetic resonance imaging 
(MRI). Upon an AS diagnosis, patients should engage in healthy lifestyle changes, non-
impact exercise, and taking NSAIDs as the first pharmacological treatment. Symptoms 
unresolved by NSAIDs are then treated with disease modifying antirheumatic drugs 
(DMARDs) and/or biologic medications like a monoclonal TNFα antibody to prevent 
further disease progression. Continued research to understand the association between AS 
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and interleukin (IL)-17/IL-23 is needed for development of additional biologic 
treatments.  
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A Review of Ankylosing Spondylitis 
Ankylosing spondylitis (AS) is a complex auto-immune disorder with a 0.5-0.9% 
global prevalence that affects males two to three times more often than female patients 
(Jamshidi et al., 2014; Sieper, Braun, Rudwaleit, Boonen, & Zink, 2002). Ankylosis of 
the vertebrae and surrounding connective tissues, especially within the sacroilial joints, 
leads to reduced mobility of the spine and rib cage. AS characteristically develops in  
early adulthood between the ages of 20 and 40 years-old and tends to worsen with age as 
the disease progresses (Calin, 1984). While a human leukocyte antigen (HLA)-B27 gene 
mutation often corresponds with an AS diagnosis, the etiology of the disease remains 
unknown. A distinctive pathogenesis is also unknown. The disease’s correlation with 
HLA-B27, increased IgA antibody levels in mucus, and chronic inflammatory histology 
suggest AS develops from excessive immune mediated responses, but the exact 
mechanism of action is still to be determined (Westerveld, Verlaan, & Oner, 2009). This 
review serves as an additional resource to educate primary care physicians and others 
about the theorized pathology, physiology, and treatments associated with ankylosing 
spondylitis.  
Pathology 
Enthesitis is often considered a hallmark of AS, possibly the root condition 
leading to ankylosis. The condition refers to inflammation of an inserted structure of 
connective tissue onto a bone, such as a ligament, tendon, or sheath of fascia. 
Fibrocartilage of the bone at the enthesis site appears to be targeted by autoimmune 
responses in AS (Sieper et al., 2002). Bone marrow biopsies from AS patients (AS+ bone 
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marrow) showed evidence of edema (swelling due to increased presence of fluid) with 
elevated levels of Cluster of Differentiation 8+ (CD8+) cytotoxic T cells (kill infected or 
cancerous self cells), CD3+ T cells, CD4+ helper T cells (activate innate immunity cells 
like macrophages), and CD20+ B cells. These findings indicated an active immune 
response occurred within sterile bone marrow of AS patients, meaning no exogenous 
pathogens such as viral or bacterial infections initiated this auto-immune response. The 
immune cells present appeared to actively break down enthesis fibrocartilage surrounding 
vertebral facet joints with their associated ribs and neighboring vertebrae as well as the 
entheses’ articulating bone tissue, which was also comprised of fibrocartilage. Other 
areas of noted damage included fibrocartilaginous entheses about peripheral joints, like 
the hip and knee, and entheses along the shafts of long bones, such as the insertion of the 
tibialis anterior muscle onto the tibia (bone that makes up the shin). Research of the 
pathology of AS finds that inflammatory destruction not only affects the entheses of the 
spine, but also damages the annulus fibrosus (fibrous exterior portion of the intervertebral 
disc that connects one vertebral body to another via ligamentous structures seen in Figure 
1) which fuses neighboring vertebral bodies over time (Sieper et al., 2002).  
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Figure 1. Illustration of human spine with identified compartments of the intervertebral disc and the spinal 
cord (sourced from http://www.bionebio.com/startling-top-human-anatomy-and-physiology-of-the-spine-
pictures/pulposus-anatomy-and-physiology-of-the-spine-spinal-cord-spinal-nerves-nucleus-intervertebral-
disc-annulus-fibrosus-pinal-cord-is-located/ under Pulposus Anatomy and Physiology of the Spine). 
 
Regarding the vertebral column, an influx of mononuclear immune cells directly 
correlates with osteitis (inflammation of the bone) and edema within AS+ bone marrow, 
thus indicating an autoimmune response on the non-infected bone marrow. T cells most 
likely initiate a response after activation by a self-antigen of cartilaginous descent to 
ultimately induce the lysis of cartilaginous support cells through an inflammatory 
immune response. This lysis damages healthy cartilaginous tissue to form an ankylosed 
or “bamboo” spine, seen in Figure 2. This outcome is classic for an AS patient after 
ossification occurs (Sieper et al., 2002).  
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Figure 2. Radiographic image of an ankylosed spine, also known as “bamboo spine.” The arrows indicate 
marginal osteophytes, ossified outgrowths of the degenerated cartilage between vertebral joints shown. 
(Image sourced from Dr. Donald Corenman of the Steadman Clinic.)  
 
Within Jethwa and Bowness’s 2016 research, three mechanisms of AS spinal 
tissue degradation were postulated regarding the vague relationship between the class I 
major histocompatibility complex (MHC) molecule HLA-B27 and the CD8+ T cells 
associated with fibrocartilage. The exact role of the HLA-B27 in AS remains unknown, 
yet three theories of inflammatory function are currently held.  HLA-B27, present on all 
nucleated somatic cells, functions as a membrane surface protein that induces a protective 
lysis response against identified foreign pathogens (Jethwa & Bowness, 2016). This 
occurs after HLA-B27 presents an intracellularly processed antigenic peptide to a CD8+ 
T cell to initiate an immune response toward the infective agents. The first theory of 
HLA-B27 involvement in AS focuses on the proposed cross-reactivity between HLA-
B27 and host cell membrane peptides that occasionally occurs. For unknown reasons, 
HLA-B27’s inability to recognize certain host cells as “self” induces an immune response 
on these cells of the host tissue rather than the invading microorganisms themselves, thus 
Removed due to Copyright 
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giving rise to an auto-immune pathology. When HLA-B27 reacts to self-antigens in this 
dysfunctional manner, the peptide can be classified as arthritogenic as it initiates an 
undue inflammatory response. The second theory states that genetically mutated HLA 
surface peptides induce an intracellular inflammatory response within its leukocyte’s 
endoplasmic reticulum (ER) (the organelle in which protein synthesis and folding 
occurs). The final theory suggests that the innate immune system targets misfolded HLA 
proteins and destroys them through an inflammatory response (Jethwa & Bowness, 
2016). Leukocyte presentation of mutated HLA-B27 in AS may induce their own 
destruction as immune cells, particularly natural killer (NK) cells, target the HLA-B27 
homodimer with the killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2); Chan et 
al. found that patients with spondyloarthritic and enthesistis-related arthritic diseases 
have elevated expression of CD41+ T cells and the KIR3DL2 receptor on NK cells 
(Chan, Kollnberger, Wedderburn, & Bowness, 2005). Localized inflammation upon 
HLA-B27 homodimer and KIR3DL2-containing cell binding occurs through the T helper 
cell production of interleukin 17 (IL-17; a pro-inflammatory cytokine induced by IL-23). 
Increased numbers of these KIR3DL2 associated cells and a raised concentration of IL-17 
were collected from the synovial fluid of spondyloarthritic patients while in AS 
specifically, a raised number of IL-17 associated immune cells were isolated from the 
spinal facet joints (Appel et al., 2011). 
Research conducted with identical twins concludes this relationship between AS 
and HLA-B27 cannot be the only cause of AS; other genes outside the HLA coding 
region can be collectively responsible for disease development. Nearly 5-10% of patients 
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diagnosed with AS are HLA-B27 negative, which suggests that multiple mutations 
collectively cause the disease. As of 2016, Ellinghaus et al. presented AS as genetically 
linked to Crohn’s disease (CD), primary sclerosing cholangitis (PSC), psoriasis (PS), and 
ulcerative colitis (UC) and thus expresses a high rate of comorbidity with these other 
autoimmune diseases. Ellinghaus et al. concluded the significant association of AS and 
these disorders are due to pleiotropy (one gene or gene  affecting multiple phenotypic 
conditions), supported by their finding of 166 related, genome-spanning loci not 
associated with major histocompatibility complex (MHC) gene regions (Ellinghaus et al., 
2016). These AS related loci were determined to mainly affect natural killer (NK) cells, 
CD34+ bone marrow cells, and undifferentiated immune cells by altering regulatory 
immune response pathways and the hematopoietic system. Typical T cells found in AS 
patients tend to secrete abnormally lower levels of tumor necrosis factor ɑ (TNFɑ), a pro-
inflammatory cytokine used to signal the destruction of pathogens and tumor cells by 
immune cells, and IL-10, a regulatory cytokine that facilitates the extent of an immune 
response by managing the concentrations of several pro-inflammatory cytokines (Sieper 
et al., 2002). A deficiency in these particular cytokines often prevents effective innate 
inflammatory responses against viral and bacterial pathogens which leads to either serial 
or chronic infections. With continued exposure to these viral or bacterial antigens, the 
risk of cross-reactivity between adaptive immune cells and continuously infected tissue 
increases greatly and may lead to development of autoimmune diseases (Sieper et al., 
2002). Other such environmental factors like an altered microbiome within the gut and 
exposure to certain toxins or drugs can also collectively lead to the pathogenesis of AS 
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(Jethwa & Bowness, 2016). Overall genetically, AS appears to require multiple gene 
mutations for an active disease state with HLA-B27 taking about 30% of the genetic 
threat. Mutations within the respective genes that code for endoplasmic reticulum 
aminopeptidase 1 (ERAP1) (an ER enzyme that packages peptides, including HLA-B27, 
for surface presentation), the IL-23 receptor (IL-23R), and other genes associated with 
the IL-17/IL-23 pathway follow HLA-B27 in prevalence (Jethwa & Bowness, 2016). 
The most recent pathological research conducted in regard to autoinflammatory 
diseases like AS focuses on the IL-17/IL-23 pathway. T helper 17 (Th17) cells stem from 
the regulatory branch of the helper T cell family and are notable for their IL-17 
production and maintenance of mucosal barrier integrity through pathogen destruction. 
Decreased or mutated Th17 populations have been connected to chronic inflammatory 
states, dysregulation of healthy gut microbiomes that allow pathogenic colonization, and 
often autoimmunity (Hartigan-O'Connor, Hirao, McCune, & Dandekar, 2011).  Sherlock 
et al.’s 2012 research involving murine models indicated that extrinsically introduced IL-
23 to healthy mice facilitated the development of symptoms associated with 
spondyloarthritis. This phenotype occurred through IL-23 action toward various T cells 
receptors, namely IL-23R which induced a fairly instantaneous inflammatory response in 
local enthesis tissue without additional immune involvement, and caused increased 
production of pro-inflammatory cytokines, especially IL-17, along with other chemokines 
for later innate and adaptive immune responses (Sherlock et al., 2012). Autoinflammatory 
responses within the enthesis were assumed to be mediated by IL-17 associated immune 
cells without regulatory capability because Th17 cells were not isolated from localized 
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enthesis inflammation (Appel et al., 2011). Increased concentrations of IL-23 producing 
cells, as well as elevated IL-17 and IL-23 serum concentrations, have been isolated from 
AS+ subchondral bone marrow and synovial fluid when compared to healthy patients 
(Davidson et al., 2011). More research regarding IL-23’s mediation of Th17 cytokines 
and their subsequent inflammatory response should be conducted to further clarify the 
pathway depicted in Figure 3 and better understand its association with AS pathology.  
 
Figure 3. Extended pathway of interleukin (IL)-17 and IL-23 (Jethwa & Bowness, 2016). 
 
Physiology  
Cardiovascular Physiology 
AS manifests itself in different ways over the course of a patient’s life, affecting 
the cardiovascular (CV), musculoskeletal, and neurological systems in detrimental ways. 
Certain serum protein levels are quite abnormal for AS patients. Increased levels of 
fibrinogen (a glycoprotein that aids in blood clot formation), IL-6 (a pro-inflammatory 
cytokine), and C-reactive protein (CRP; a protein used to indicate levels of inflammation 
in the body as it binds to phospholipids of damaged cells to initiate the innate immune 
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system response through the complement pathway) raise the viscosity of blood, which 
increases its likelihood to clot and mount a defense against self-antigens throughout the 
spine, entheses, peripheral joints, and other AS manifestation areas. These higher protein 
concentrations raise the erythrocyte sedimentation rate (ESR) which also increases the 
viscosity of the blood. AS patients are more likely to suffer from strokes and myocardial 
infarctions (MI) since blood clots form more readily and the arteries tend to be coated 
with fatty plaques. For unknown reasons, AS patients present with decreased levels of 
triglycerides and total body cholesterol, especially high density lipoproteins (HDLs) 
which regulate plaque formation in the arteries. This decrease in HDL leads to a greater 
prevalence of atherosclerosis in AS patients; these patients are twice as likely to 
experience strokes and MIs compared to healthy individuals (Park et al., 2012).  
As the disease progresses, AS patients undergo an abnormal thickening of their 
mitral and aortic valves as marks of high blood pressure and continual systematic 
inflammation. Along with thickening of the heart valves, the thickening of the intima-
media (innermost layer of an artery wall), especially within the carotid arteries, increases 
significantly with age (Mathieu, Gossec, Dougados, & Soubrier, 2011). These heart valve 
changes most likely occur after disease onset without noticeable effects to the patient 
(Park et al., 2012). Usten et al. measured left ventricular systolic function in AS patients 
with highly sensitive speckle tracking echocardiography (STE) rather than the commonly 
used conventional and Doppler echocardiography (ECG) techniques. Both the 
conventional and Doppler ECG machines are incapable of detecting minor ventricular 
dysfunctions (Ustun et al., 2015). The use of STE quantified significantly lower left 
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ventricular systolic and diastolic strain measurements with all STE parameters in AS 
patients compared to controls. These findings indicated weakened overall function of the 
left ventricle possibly due to systemic inflammation that damages cardiomyocytes 
(muscle cells of the heart) over the course of the disease.  
Musculoskeletal Physiology 
As previously discussed, AS mainly debilitates the skeletal system at its 
cartilaginous sites like the spinal joints (articulating its superior and inferior vertebra and 
lateral ribs), the peripheral joints, and the entheses throughout the spine and other 
individually symptomatic areas. Activated immune cells targeting AS-associated self-
antigens break down cartilaginous fibers of joints and entheses until the damaged tissues 
begin to ossify, producing new bone tissue in the place of flexible attachment sites for 
tendons, ligaments, and fascia. Ossified joints and entheses result in decreased mobility. 
Original flexibility diminishes, reducing physical strength and increasing AS-associated 
back and joint pain particularly during sedentary periods. As stated earlier, complete 
fusion of vertebral bones may occur in the axial spine when the outer linings of the 
intervertebral disks begin to ossify, creating what is known as “bamboo spine.” Fused 
spines like this fracture easily under trivial traumas, like bumping into a stranger, and 
heal poorly; they lack stability and durability as the disease progresses and greatly 
increase neurological complications during serious traumas involving the cervical spine 
(Westerveld et al., 2009). A prematurely stiff or nearly fused spine also constricts 
expansion of the rib cage which restricts airflow into the lungs below a normal level 
(McBride, King, Baikie, Crean, & Sircus, 1963). A constricted rib cage raises stress on 
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the pulmonary and CV systems, leading to reduced oxygen intake and increased heart 
rate that accounts for the structural changes in the heart and arteries.  
Neurological Physiology 
 The autoinflammatory nature of AS alters proper function of both the central 
nervous system (CNS; neurons associated with the brain and spinal cord) and the 
peripheral nervous system (PNS; neurons outside the CNS). The hypothalamic-pituitary-
adrenal (HPA) axis is comprised of three separate endocrine organs that together regulate 
and counteract stress, immune responses, emotions, and metabolic expenditure. When 
tested in AS patients via the standard insulin tolerance test (ITT), the HPA axis will 
present normally when compared to control subjects, unlike similar rheumatic diseases 
like rheumatoid arthritis (RA) (Kirnap et al., 2008). A statistically insignificant, mild 
decrease in adrenal function was noted in tested AS subjects based on their abnormally 
lower basal cortisol levels prior to ITT testing. These results were possibly attributed to 
patients’ previous NSAID treatments or how increased levels of pro-inflammatory 
cytokines, mainly IL-1, IL-6, and TNFα, appeared to raise adrenocorticotropic hormone 
(ACTH) levels through modifying the effects of corticotrophin-releasing factor (Imrich et 
al., 2004). Further dynamic testing indicated no significant adrenal malfunction was 
present with AS patients (Kirnap et al., 2008).  
 Although the hypothalamus and pituitary gland appear unchanged within the AS 
brain, other networks of the brain involving attention, executive control, and somato-
sensory function restructure with the course of the disease and communicate poorly. 
Significant reported fatigue in AS patients was inversely correlated with quantified spinal 
ANKYLOSING SPONDYLITIS  15 
 
 
 
mobility and emotional stamina; gray matter (neuronal bodies of the CNS associated with 
sensory perception, emotions, and decision-making capabilities) within the attention 
networks, somatosensory cortices (areas of the cerebrum that facilitate thoughts and 
perceptions into physical actions), and caudate nucleus (segment of brain that assists 
regulating goal-directed actions, memory, learning, and attention stabilization) were also 
negatively correlated with fatigue scores (Wu, Inman, & Davis, 2014). This indicates that 
AS patients experiencing an active disease state often have difficulty processing external 
stimuli appropriately and accomplishing higher cognitive goals. AS patients also tend to 
endure continuous neuropathic pain (perceived pain associated with malfunctioning of 
the somatosensory nervous system rather than damaged tissue) in which atrophy of gray 
matter in the aforementioned brain regions generally leads to poor control of the limbic 
system (midbrain regulator of emotions) and pain modulating centers (Wu, Inman, & 
Davis, 2013). AS neuropathic pain usually involves “shooting” or “stabbing” pain in 
individual problem areas along with dull, achy soreness associated back pain stemming 
from inflammation surrounding spinal nerves.  
Diagnosis 
Historically, the concept and manifestations of AS were poorly understood by 
physicians until the mid-1900s. The first AS-focused studies associated the disease with 
other forms of inflammatory arthritic diseases like psoriatic arthritis, rheumatoid arthritis, 
Reiter’s disease, and inflammatory bowel disease (Sieper et al., 2002). By 1991, the 
clinical grouping of the aforementioned spondylarthropathies (SpAs) was modified by the 
European Spondylarthropathy Study Group (ESSG) to allow for more distinctive 
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diagnoses between the diseases (Dougados et al., 1991). All these auto-immune disorders 
share common symptoms like arthritic joint pain, stiffness, and the like although their 
immunological mechanisms are not identical because they often require different 
treatments. A proper ankylosing spondylitis diagnosis requires a patient to fall within a 
younger adult age set and present with a specific combination of symptoms within a 
designated time constraint for the onset of severe symptoms. These AS diagnosis 
qualifications were detailed in the New York Criteria for Ankylosing Spondylitis 
published in 1973 and act as the current standardized basis for scientists diagnosing 
research participants before undergoing any AS studies. 
 In the early 1960s, the minimum requirements for an AS diagnosis were “bilateral 
loss of definition or irregularity of the sacro-ilial spaces with subchondral sclerosis” 
(McBride et al., 1963). No discussion of the ankylosis of the cervical spine or accessory 
symptoms (like the now hallmark uveitis and enthesitis) occurred, which left this 
diagnostic system incomplete and unable to differentiate between multiple SpAs.  A more 
complete evaluation of AS symptoms was compiled in the original 1973 New York 
Criteria diagnostic list as follows: 1) low back pain and stiffness lasting more than 3 
months that is not alleviated by rest, 2) pain and stiffness in the thoracic region, 3) limited 
motion of the lumbar spine, 4) limited chest expansion, 5) history of iritis or its sequelae, 
and 6) x-rays showing bilateral sacroilial changes characteristic with ankylosing 
spondylitis (excluding bilateral osteoarthrosis of the sacroilial joints) (Moll & Wright, 
1973). Over the years, the need for a more comprehensive diagnostic system grew with 
the collection of additional pathological and physiological information about AS; 
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multiple researchers then modified the New York criteria to include extra differential 
symptoms and characteristics of the current patient population seen in Table 1. Calin et 
al. made additional requirements of “AS onset before age 40” and the “onset of disease is 
insidious in nature” to better match the data of his sample and review populations (Calin, 
Porta, Fries, & Schurman, 1977). 
 
Table 1. Modified Criteria for Ankylosing Spondylitis (Sieper et al., 2002).  
Radiologic criterion 
Sacroiliitis, grade ≥II bilaterally or grade III to IV unilaterally 
Clinical criteria 
Low back pain and stiffness for more than 3 months that improves with exercise that is not relieved by rest 
Limitation of motion of the lumbar spine in both the sagittal and frontal planes 
Limitation of chest expansion relative to normal values correlated for age and sex 
 
Note: The condition is definitely AS if the radiological criterion is associated with at least 1 clinical 
criterion. 
 
Physicians analyze a patient’s symptoms with the previously mentioned criteria in 
mind to monitor alignment of symptoms with an AS diagnosis using a diagnostic 
algorithm, seen in Figure 3.  
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Figure 3. Diagnostic algorithm for axial SpA (early AS) starting with the assessment of 
inflammatory back pain (Sieper et al., 2002). 
 
Confirmed symptoms farther down the pyramid of Figure 1 carry more diagnostic 
weight than those near the top due to the narrowly direct association with the disease. 
Accessory symptoms to inflammatory arthritis of the axial skeleton include enthesitis 
(inflammation of the enthesis that joins bone to collagen fibers of tendons, ligaments, and 
fascias), uveitis (inflammation of ovea, the middle layer of the eye), asymmetric arthritis 
of the peripheral joints, family history of the disease, a confirmed HLA-B27 gene 
mutation, raised C-reactive protein levels in the blood (CRP), and a positive response to 
NSAIDs. At least two of these accessory symptoms must be present in addition to 
spondylitis and radiographic evidence of sacroiliitis for an AS diagnosis to be made. A 
positive HLA-B27 genetic test is one of the strongest indicators of active AS. 90-95% of 
those diagnosed with the disease also have a mutation within an HLA-B27 coding region 
(Sieper et al., 2002). 
Removed due to Copyright 
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 Upon diagnosis, physicians have often incorporated the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) as a functional scale to measure the 
severity of a patient’s disease and provide quantitative data regarding the efficacy of a 
newly applied treatment. The BASDAI reliably compiles a scaling of six major AS 
complaints: 1) fatigue severity; 2) pain in spinal joints; 3) swelling and pain in peripheral 
joints; 4) enthesitis severity (worded as “localized tenderness”); 5) duration of morning 
stiffness; and 6) severity of morning stiffness (Li et al., 2016). Patients can quickly record 
their personal evaluation of each symptom with a 1-10 scale (1 indicating no issue and 10 
indicating the severest issue) in which each of the first four symptoms are given equal 
weight with the averaged morning stiffness symptom scales. This creates a 0-50 scale that 
is then divided by 5 for an official 0-10 BASDAI score used to rank and compare total 
AS severity among patients (Chung, Lau, Wu, Wong, & Mok, 2011). A BASDAI score 
of 4 or greater indicates poor disease management; these patients are prime candidates for 
altering their present treatment, possibly to include a biologic medication like a TNFα 
antibody. Clinical researchers use the BASDAI to identify appropriate candidates for new 
drug trials geared toward slowing AS progression and measure the success of the 
treatment. Aside from the BASDAI, other disease scoring tests specifically for AS are 
commonly used, such as Bath Ankylosing Spondylitis Metrology Index (BASMI) and the 
Ankylosing Spondylitis Disease Activity Score (ASDAS), though the BASDAI is 
considered the “gold standard” for AS disease scoring (Zochling, 2011).  
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Treatments 
Prior Treatments 
The advancements in treating AS have become safer, more comprehensive, and more 
effective since the early 1900s. Before the 1950s, physicians attempted to treat AS 
symptoms with several rounds of x-ray therapy over the course of several months. The 
theorized goal of this therapy was to stimulate hormones that were presumably 
unbalanced to induce mast cells release of their higher concentration of sulfur. At the 
time, researchers believed mast cells, as well as other leukocytes, carrying more sulfur 
than usual absorbed it from cartilaginous fibers surrounding the sacroilial joints, thus 
damaging the cartilage which would then heal as bone tissue: the proposed etiological 
origin of AS (Tegner, 1946). A more involved understanding of the immune system as a 
whole and its specific relationship with AS proved this prior theory false. Although x-ray 
therapy relieved pain in treated patients, this now controversial treatment plays no role in 
preventing disease development today. No changes in bone sedimentation of inflamed 
joints or radiographic evidence of spinal damage were noted during the course of x-ray 
therapy, so the treatment was deemed ineffective in controlling the progression of AS. 
Even though the continual exposure to x-rays decreased a patient’s pain, the treatment 
was discontinued throughout the United States when further research indicated that 
increased rates of cancer in AS patients stemmed from the carcinogenic therapy.   
Non-pharmacological Treatment 
One treatment doctors have reached a consensus on is the incorporation of 
physical activity into the daily lives of AS patients. Research finds that individuals with 
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AS who held a consistent exercise program over 4 months increased the function of their 
spine and peripheral joints significantly compared to sedentary AS patients (Zochling, 
van der Heijde, Dougados, & Braun, 2006). This study conducted by Zochling et al. 
(2006) compared the exercises prescribed and supervised by a licensed physical therapist 
to patient organized daily movement at home to see if one particular regime decreased 
AS stiffness and pain more than the other. Zochling et al. concluded that neither regime 
was more effective than the other; simply moving the joints and raising the heart rate 
consistently alleviates much of the symptomatic stiffness. They also found that while 
exercise decreased the patients’ overall stiffness, their subjective levels of pain remained 
relatively the same as before exercise. Impact exercises, such as running and contact 
sports, are high risk activities for patients with active AS. Jarring movements associated 
with these exercises cause additional stress on the joints and spine an AS patient is unable 
to heal properly since damaged fibrocartilage is mistakenly converted into bone tissue, 
increasing the risk that injury could hasten the rate of disease progression (Zochling et al., 
2006). Impact sports could potentially fracture a delicate, ankylosed spine which may not 
heal to regain functionality. Non-impact physical activities like bike riding, swimming, 
yoga, and gentle power walking are highly recommended exercise alternatives for AS 
patients.  
Other recommended non-pharmacological lifestyle changes for AS include 
educating patients concerning their disease, its treatments, and daily restrictions; drinking 
alcoholic beverages in moderation; avoiding smoking and using recreational drugs; 
remaining hydrated throughout the day; eating a diet low in starches and sugars, possibly 
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adhering to a gluten-free and sugar-conscious diet, to avoid disease flare ups;  and 
committing to an appropriate sleeping regimen that includes at least 7 hours of sleep per 
night (Zochling et al., 2006). Since an abnormal sleep schedule may further aggravate the 
chronic inflammatory state, patients are recommended to adopt consistent sleeping habits 
as newer research correlates adequate sleep with possible disease remission (Leverment, 
Clarke, Wadeley, & Sengupta, 2017). The maintenance of mental health is also especially 
important. Emotional stress left unchecked in an AS patient has the potential to increase 
the diagnosis of depressive and anxiety disorders, along with a heightened level of 
disease related pain. In a state of depression and anxiety, patients may be mentally unable 
to complete their treatment of AS by remaining isolated and sedentary within their 
homes, possibly avoiding exercise, increasing or decreasing eating, sleeping too much or 
too little, and taking their medications in ways other than as prescribed. Patients 
experiencing symptoms of depression along with their AS diagnosis should seek help 
from a medical professional, either their general care doctors or a psychiatrist, and a 
licensed counselor to discover the cause of these psychological concerns (Basler & 
Rehfisch, 1991).  
Non-steroidal Anti-inflammatory Drugs (NSAIDs) 
NSAIDs are considered the cornerstone of AS therapy; NSAIDs are the cheapest 
and longest studied drugs used to treat ankylosing spondylitis. These drugs exhibit 
analgesic (relief from pain) and antipyretic (reduction of fever) properties by inhibiting 
cyclooxygenase 1 and 2 (COX-1 and COX-2), enzymes that assist in antibody synthesis 
and catalyze prostaglandins that regulate several physiological responses during local and 
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systemic inflammation (Bancos, Bernard, Topham, & Phipps, 2009). NSAIDs also 
clinically modify multiple other branches of the innate and adaptive immune system 
through the reduction of T lymphocyte activation and proliferation, monocyte activation, 
cytokine production, and formation of leukotrienes.  
Diclofenac, the most prescribed NSAID for AS, has been found effective and safe 
in treating AS in long-term cases and short-term flare ups (Calabro, 1986). Typically, 
75mg of diclofenac twice daily is enough to provide a therapeutic effect to treat 
predominantly axial manifestations of the disease as well as peripheral joint arthritis and 
enthesitis. Though the half-life of diclofenac lasts about an hour or two, the drug 
continues to work actively in synovial fluid for up to 11 hours (Small, 1989). 200mg 
daily of celecoxib, another commonly prescribed NSAID for AS patients, has the same 
efficacy of treatment as diclofenac with fewer adverse gastrointestinal side effects (Sieper 
et al., 2008). The mechanism of action for NSAIDs indirectly weakens the epithelium of 
the stomach by the reduction of prostaglandin production, leading to the main adverse 
effect of NSAIDs: stomach ulcers and increased sensitivity to gastric acid corrosion. 
Since NSAIDs have long been the premier treatment of AS, a patient must undergo two 
failed NSAID trials before a presiding rheumatologist considers alternative treatments to 
include tumor necrosis factor-ɑ (TNFɑ) blockers, discussed later in this review.  
Disease-modifying Antirheumatic Drugs (DMARDs) 
Low doses of DMARDs are also considered safe, first action drugs for AS. Anti-
malarial drugs, gold salts, various immunosuppressants, and methotrexate can be 
incorporated into auto-immune disease treatment in general, with methotrexate as the 
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chief drug of the list to treat AS. Overall, normal AS patients tolerate DMARDs well 
with few serious side effects. (Pregnant patients should avoid methotrexate since the drug 
acts as an abortifacient; patients fighting an infection should avoid penicillins because the 
two drugs combined can lead to a fatal reaction.) Methotrexate’s method of action 
inhibits the metabolism of folic acid, then inhibiting the activation of T cells by 
suppressing the intercellular adhesion molecules between T cells, causing B cells to 
selectively down-regulate, and inhibiting interleukin 1 ß cell surface receptors to 
effectively decrease the immune responses capable of damaging an AS patient’s joints 
and entheses (Chen, Veras, Liu, & Lin, 2013). Research finds that a 12.5mg 
intramuscular injection of methotrexate once-weekly is effective to treat morning 
stiffness, disease intensity, and axial and peripheral joint functionality in older AS 
patients and patients in a later disease state. The state of disease progression can be 
physically viewed through radiographic imaging of the sacroilial joints as well as 
recording the range of mobility in affected joints using a goniometer. Methotrexate is 
often synergistically paired with infliximab, a TNFɑ blocker, to treat cases of AS 
ineffectively reduced by NSAIDs use. Methotrexate and other DMARDs should not be 
paired with NSAIDs; the combination of the drugs could cause a potentially fatal reaction 
(Chen et al., 2013).  
Monoclonal TNFɑ Antibodies 
TNFɑ is presumed to be a pivotal cytokine in AS pathogenesis; TNFɑ and other 
cytokines in its cascade pathway can be consistently collected from the synovial fluid, 
serum, and sacroilial joints of patients in an active disease state (Gorman, Sack, & Davis, 
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2002). Anti-TNFɑ drugs, usually a monoclonal human antibody, have proven some of the 
most effective drugs at treating spinal structures and peripheral entheses and preventing 
disease progression, which can be viewed via radiographic evidence. Extended treatment 
with anti-TNFɑ antibodies induces an immunosuppressive state in which the patient is 
more susceptible to illnesses like tuberculosis, influenza, and certain types of cancers, but 
many physicians believe the benefits of the drug sharply outweigh the risks of further 
illness. Three anti-TNFɑ agents are currently approved for use in the US and the UK: 
infliximab, etanercept, and adalimumab which are sold under the trade names Remicade, 
Enbrel, and Humira, respectively. Normally paired with a methotrexate drug, infliximab 
is a monoclonal antibody that binds up TNFɑ and is infused intravenously over 1-2 hours 
every 8 weeks (Braun et al., 2003). Etanercept is a small molecule that competes for the 
TNF-ɑ receptor on cell surfaces, administered to patients in 25mg increments via 
subcutaneous injection twice weekly (Braun et al., 2003). The last anti-TNFɑ drug, 
adalimumab, is a 40mg portion of a monoclonal human anti-TNFɑ antibody injected 
subcutaneously biweekly. Even from the limited studies concerning the newly developed 
technology, researchers have concluded that these three anti-TNFɑ drugs, especially 
adalimumab, possess an extremely high efficacy in treating AS.  
Since these drugs were only recently developed, long term effects on organs and 
their systems are currently unknown and the cost of production remains extremely 
expensive, with the retail price costing upwards of $1000 US per injection. Anti-TNFɑ 
antibodies have also been linked to new cancer diagnoses, especially lymphomas, 
following continued drug administration. Doctors and insurance companies try to reserve 
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these costly medicines for those with the most severe cases of AS that cannot be 
controlled through other methods. Requirements for a TNFɑ blocker prescription include 
1) a diagnosis of AS according to the New York criteria previously described (including 
radiographic evidence of sacroiliitis); 2) failure of at least 2 adequate trials of NSAID 
therapy; 3) persistence and worsening of disease activity; 4) threat of severe damage from 
disease; and 5) likelihood of response to a TNFɑ blocker as determined by the 
rheumatologist. Once a patient’s conditions expresses these five conditions, a presiding 
doctor can then prescribe one of the three drugs. If patients become actively diagnosed 
with certain autoimmune disorders, infection, malignancy, or becomes pregnant, they are 
disqualified from receiving TNFɑ blockers. Due to the potential cancerous side effects, 
high cost, and high efficacy of the TNFɑ blocker drugs, doctors recommend infliximab, 
etanercept, and adalimumab be taken in 6-12-week intervals after which the monitoring 
physician assesses the level of disease improvement. If less than 50% relative 
improvement occurs during the 6-12-week time period, the patient continues taking the 
drug through the next period. If a patient experiences a relative improvement greater than 
50%, the drug is discontinued during the next 6-12 week interval until the patient begins 
to deteriorate again (Braun et al., 2003).   
Proposed Therapies 
Currently, no other biologic treatments specifically approved for AS are available 
to patients beside TNFα blockers. New, promising research involving the treatment of 
plaque psoriasis, a dermatological autoimmune disease genetically linked to AS, with 
biologic drugs ixekizumab, secukinumab, and ustekinumab (respective trade names: 
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Taltz, Cosentyx, and Stelara; respective market release: 2016, 2015, and 2013) could lead 
to possible treatments for AS (Ellinghaus et al., 2016). Ixekizumab and secukinumab are 
both monoclonal antibodies that target IL-17 cytokines within the IL-23-T helper 17 
pathway. According to Gomez-Garcia et al. (2016), both drugs were found more 
efficacious in treating plaque psoriasis in Japanese patients than TNFα monoclonal 
antibodies in short-term therapy yet both were more likely to lead to drug complications: 
infliximab use increased the risk for adverse effects (AE) other than infections while 
secukinumab increased patients’ susceptibility to infection (Gomez-Garcia et al., 2016). 
Ustekinumab, a monoclonal antibody that binds to the shared protein subunit between IL-
12 and IL-23, also exhibited significant efficacy in treating plaque psoriasis in the 
aforementioned study. Ustekinumab presented as the highest ranked efficacy-safety 
profiled drug tested by Gomez-Garcia et al. (2016), including ixekizumab, secukinumab, 
and popular TNFα antibodies, namely etanercept and adalimumab (Gomez-Garcia et al., 
2016). Brodalumab is a monoclonal antibody not yet approved by the Food and Drug 
Administration (FDA) that functions as a competitive inhibitor for the IL-17A receptor 
that showed promise in treating plaque psoriasis effectively (Nakagawa, Niiro, Ootaki, & 
Japanese brodalumab study, 2016). These biologic drugs that prove effective in treating 
psoriatic patients should be further investigated especially in regard to possible treatment 
of AS. Preliminary research to understand the IL-23/IL-17 pathway in AS pathogenesis is 
currently underway in hopes of leading to clinical trials involving the aforementioned 
drugs (Jethwa & Bowness, 2016). 
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Ankylosing spondylitis is an auto-inflammatory disorder that targets cellular 
surface molecules associated with fibrocartilage within entheses throughout the body, 
mainly within the axial spine, resulting in reduced patient mobility and quality of life. 
Cross-reactive immune cells, often expressing an allotype of HLA-B27 with the 
abnormal ability to present self-antigens, illicit damage at these fibrocartilaginous sites 
before the tissue heals as bone. Extensive deposition of bone in these tissues may produce 
the “bamboo spine” characteristic to AS. Since the aforementioned cross-reactive 
immune cells have constant access to their fibrocartilaginous auto-antigens, the body 
experiences a state of chronic inflammation perpetuated in part by the IL-17/IL-23 
cytokine pathway. Adverse cardiovascular and neurological effects associated with AS 
stem from generalized chronically activated immune and chronic pain states, 
respectively, while the musculoskeletal effects are more exclusive to the specific disease. 
Proper diagnosis requires simultaneous presentation of multiple symptoms including, but 
not limited to, insidious onset of back pain and stiffness lasting more than 3 months, 
limited expansion of the ribcage, a positive response to NSAIDs, a positive test for HLA-
B27 mutation, peripheral arthritis, uveitis, enthesitis, and radiologic evidence of 
sacroiliitis. Upon diagnosis, several courses of treatment exist for AS patients ranging 
from healthy lifestyle changes to immunosuppressant antibody drugs. General 
practitioners and rheumatologists recommend their AS patients avoid high-impact 
exercise, smoking, the consumption of alcoholic beverages, gluten-based food products, 
and irregular sleeping habits. Patients are encouraged to educate themselves regarding 
their disease limitations in addition to preserving their mental health and partaking in 
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core-strengthening exercises. More severe cases of AS often require pharmaceutical 
intervention with a combination of NSAIDs, DMARDs, and anti-TNFα antibodies, all of 
which should depress the overactive immune system response for symptom relief and 
slow disease progression. Each class of drug has its own list of benefits and drawbacks 
that should be considered in totality prior to creating a patient’s treatment plan.  
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